Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027)

被引：0
|
作者：
Lai, Ching-Lung
Chang, Ting-Tsung
Chao, You-Chen
Tanwandee, Tawesak
Thongsawat, Satawat
Lee, Shou-Dong
Angus, Peter
Zink, Richard
Zhu, Jin
Brett-Smith, Helena
Neo, Boon-Leong
机构：
[1] Queen Mary Hosp, Hong Kong 70101, Peoples R China
[2] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan
[3] Tri Serv Gen Hosp, Taipei 10700, Taiwan
[4] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[5] Maharajnakorn Chiang Mai Hosp, Chiang Mai, Thailand
[6] Taipei Vet Gen Hosp, Taipei, Taiwan
[7] Austin & Repatriation Med Ctr, West Heidelbrg, Vic, Australia
[8] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [21] CONTINUED TREATMENT OF EARLY NONRESPONDER OR PARTIAL VIROLOGIC RESPONDERS WITH BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD) THROUGH WEEK 96 LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES
    Lampertico, Pietro
    Wedemeyer, Heiner
    Brunetto, Maurizia
    Bogomolov, Pavel
    Stepanova, Tatyana
    Ciesek, Sandra
    Berger, Annemarie
    Manuilov, Dmitry
    An, Qi
    Lau, Audrey
    Da, Ben
    Flaherty, John
    Mercier, Renee-Claude
    Zeuzem, Stefan
    Cornberg, Markus
    Buti, Maria
    Aleman, Soo
    GUT, 2023, 72 : A101 - A102
  • [22] LONG-TERM ENTECAVIR THERAPY RESULTS IN REVERSAL OF FIBROSIS/CIRRHOSIS AND CONTINUED HISTOLOGIC IMPROVEMENT IN PATIENTS WITH HBEAG(+) AND (-) CHRONIC HEPATITIS B: RESULTS FROM STUDIES ETV-022,-027 AND-901
    Liaw, Yun-Fan
    Chang, Ting-Tsung
    Wu, Shun-Sheng
    Schiff, Eugene R.
    Han, Kwong-Hyub
    Lai, Ching-Lung
    Safadi, Rifoot
    Lee, Samuel S.
    Holota, Waldemar
    Goodman, Zachary D.
    Zhang, Hui
    Hindes, Robert
    Iloeje, Uchenno
    Beebe, Suzanne
    Kreter, Bruce
    HEPATOLOGY, 2008, 48 (04) : 706A - 706A
  • [23] EVALUATION OF THE EFFICACY OF ENTECAVIR VERSUS ADEFOVIR IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS THERAPY AT 96 WEEKS
    Sun, Aimin
    Cheng, Haowei
    Zhao, Liqun
    Yang, Huiyu
    Yang, Guojie
    HEPATOLOGY, 2010, 52 (04) : 550A - 550A
  • [24] Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: Results of phase III study ETV-026
    Sherman, M
    Yurdaydin, C
    Sollano, J
    Silva, M
    Goodman, Z
    Chen, L
    Cross, A
    Dehertogh, D
    Hindes, R
    HEPATOLOGY, 2004, 40 (04) : 664A - 664A
  • [25] Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of Phase III study ETV-026
    Sherman, M
    Yurdaydin, C
    Sollano, J
    Silva, M
    Goodman, Z
    Chen, L
    Cross, A
    DeHertogh, D
    Hindes, R
    ANTIVIRAL THERAPY, 2004, 9 (06) : H22 - H23
  • [26] Long-term entecavir (ETV) therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg positive and negative chronic hepatitis B (CHB): results from studies ETV-022,-027 and-901
    Chang, T. T.
    Wu, S. S.
    Chao, Y. C.
    Han, K. H.
    Yoon, S. K.
    Lai, C. L.
    Akbar, N.
    Liaw, Y. F.
    Tanwandee, T.
    Goodman, Z. D.
    Zhang, H.
    Hindes, R.
    Iloeje, U.
    Beebe, S.
    Kreter, B.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A178 - A179
  • [27] Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.
    Shouval, D
    Lai, CL
    Cheinquer, H
    Lok, A
    DeHertogh, D
    Wilber, R
    Cross, A
    Zink, R
    Fernandes, L
    HEPATOLOGY, 2004, 40 (04) : 728A - 728A
  • [28] QUANTITATIVE HBSAG AND HBEAG ASSAYS IN THE PREDICTION OF THE VIROLOGIC RESPONSE TO ENTECAVIR IN PATIENTS WITH CHRONIC HEPATITIS B
    Lee, Jung Min
    Kim, Hyon Suk
    Ahn, Sang Hoon
    Park, Hana
    Kim, Do Young
    Chon, Chae Yoon
    Han, Kwang-Hyub
    Park, Jun Yong
    HEPATOLOGY, 2010, 52 (04) : 504A - 504A
  • [29] Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses
    Lampertico, Pietro
    Wedemeyer, Heiner
    Brunetto, Maurizia
    Bogomolov, Pavel
    Stepanova, Tatyana
    Ciesek, Sandra
    Berger, Annemarie
    Manuilov, Dmitry
    An, Qi
    Lau, Audrey
    Da, Ben
    Flaherty, John F.
    Mercier, Renee-Claude
    Zeuzem, Stefan
    Cornberg, Markus
    Buti, Maria
    Aleman, Soo
    JOURNAL OF HEPATOLOGY, 2023, 78 : S113 - S114
  • [30] Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleosidenaive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Shouval, D
    Senturk, H
    Gish, RG
    Chang, TT
    Yurdaydin, C
    Lai, CL
    Lok, AS
    Brown, RS
    Apelian, D
    Fernandes, L
    Klesezewski, K
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 192 - 192
12345